Entropy Neurodynamics Limited has released a press release.
Disclosure Document - Replacement Prospectus
Filed with ASX ·
6ix hasn’t read this filing yet.
Entropy Neurodynamics Limited on 6ix
Story so far
Earlier from Entropy Neurodynamics
- Disclosure Document - Prospectus
- 2024 General Meeting Letter of Access, Notice and Proxy
- EX1 signs binding agreement to acquire Tryp Therapeutics
- Appendix 4D and Half Year Report for period 31 December 2023
- Further management changes and cost-reductions
Later from Entropy Neurodynamics
- Results of 2024 General Meeting
- Reinstatement to Quotation
- Maiden dosing of TRP-8803 completed in global first
- Positive Phase 2a fibromyalgia results across all patients
- Completion of patient dosing in maiden TRP-8803 trial
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics